Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia

Oncoimmunology
Xiufen ChenJustin Kline

Abstract

Exposure of cancer cells to particular chemotherapeutic agents or γ-irradiation induces a form of cell death that stimulates an immune response in mice. This "immunogenic cell death" requires calreticulin (CRT) translocation to the plasma membrane, which has been shown to promote cancer cell phagocytosis. However, it remains unclear whether the effect of CRT on cancer cell phagocytosis is alone sufficient to affect tumor immunity. Acute myeloid leukemia (AML) cells expressing cell-surface CRT were generated in order to characterize the mechanism(s) through which CRT activates tumor immune responses. Potent immune-mediated control or rejection of AML was observed in mice with CRT-expressing leukemia. The "CRT effect" was ultimately T-cell dependent, but dendritic cells (DCs), and CD8α+ DCs in particular, were also necessary, indicating that CRT might act directly on these DCs. CRT-expressing AML cells were slightly more susceptible to phagocytosis by DCs in vivo, but this effect was unlikely to explain the potent immunity observed. CRT did not affect classical DC maturation markers, but induced expression of type I interferon (IFN), which was critical for its positive effect on survival. In conclusion, CRT functions as a "danger...Continue Reading

References

Jun 25, 2003·The Journal of Cell Biology·Anthony Wayne OrrJoanne E Murphy-Ullrich
Mar 17, 2004·The Journal of Experimental Medicine·Laura C BonifazRalph M Steinman
Dec 26, 2006·Nature Medicine·Michel ObeidGuido Kroemer
Apr 28, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laurence ZitvogelGuido Kroemer
Dec 24, 2010·Science Translational Medicine·Mark P ChaoIrving L Weissman
Sep 21, 2011·The Journal of Experimental Medicine·Mercedes B FuertesThomas F Gajewski
Sep 21, 2011·The Journal of Experimental Medicine·Mark S DiamondRobert D Schreiber
Nov 3, 2011·Nature Communications·Sudesh Pawaria, Robert J Binder
Sep 29, 2012·Science·Laura SenovillaGuido Kroemer
Apr 27, 2013·The Journal of Clinical Investigation·Long ZhangJustin Kline
Aug 26, 2016·Cancer Science·Satoshi MatsukumaHiroaki Nagano

❮ Previous
Next ❯

Citations

Feb 15, 2018·International Journal of Molecular Sciences·Mohan NairSiobhan A Corbett
Mar 27, 2020·Journal for Immunotherapy of Cancer·Lorenzo GalluzziFrancesco M Marincola
Sep 20, 2020·International Journal of Molecular Sciences·Darina OcadlikovaAntonio Curti
Nov 13, 2018·World Journal of Gastroenterology : WJG·Hayandra Ferreira NaniniHeitor Siffert Pereira de Souza
Feb 1, 2020·Oncoimmunology·Jitka FucikovaRadek Spisek
Apr 14, 2017·Oncoimmunology·Lorenzo Galluzzi, Guido Kroemer
Nov 30, 2019·Frontiers in Immunology·María Julia LambertiMariana Maccioni
Jul 11, 2018·Seminars in Immunopathology·Morten Orebo Holmström, Hans Carl Hasselbalch
Aug 1, 2020·Cell Research·Jitka FucikovaLorenzo Galluzzi
Aug 28, 2021·Cancers·Francesco TarantiniFrancesco Albano

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
flow cytometry
FACS
PCR

Software Mentioned

ImmunoSpot

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.